1,002 results match your criteria Cardiology in review[Journal]


The Clinical Value of Heart Rate Monitoring Using an Apple Watch.

Cardiol Rev 2019 Mar/Apr;27(2):60-62

From the Department of Medicine, New York Medical College, Valhalla, NY.

Public interest in health monitoring devices has increased with the availability of wearable technologies or wearables such as the Apple Watch. These devices are collecting health data that may be useful to health professionals. Most studies to date have been conducted with a limited sample size and with healthy subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000243DOI Listing
January 2019
2 Reads

Angiotensin II (Giapreza®): A Distinct Mechanism for the Treatment of Vasodilatory Shock.

Cardiol Rev 2018 Dec 28. Epub 2018 Dec 28.

From the Clinical Pharmacy, Montefiore Medical Center/The University Hospital of the Albert Einstein College of Medicine, Einstein Division, Bronx, NY.

Septic shock, a form of vasodilatory shock associated with high morbidity and mortality, requires early and effective therapy to improve patient outcomes. Current management of septic shock includes the use of intravenous fluids, catecholamines and vasopressin for hemodynamic support to ensure adequate perfusion. Despite these interventions, hospital mortality rates are still greater than 40%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000247DOI Listing
December 2018
6 Reads

Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?

Cardiol Rev 2018 Dec 28. Epub 2018 Dec 28.

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

Cholesterol metabolism and transport has been a major focus in cardiovascular disease risk modification over the past several decades. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) have been the most commonly used agents, with the greatest benefit in reducing both the primary and secondary risks of cardiovascular disease. However, heart disease remains the leading cause of death in both men and women in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000245DOI Listing
December 2018
2 Reads

Cardiac Manifestations in Idiopathic Inflammatory Myopathies: An Overview.

Cardiol Rev 2018 Dec 21. Epub 2018 Dec 21.

Idiopathic inflammatory myopathies are a group of autoimmune diseases that are characterized by muscle inflammation resulting in elevated muscle enzyme release and distinctive biopsy findings. This group of conditions includes polymyositis, dermatomyositis, inclusion body myositis and necrotizing autoimmune myopathy. Although they have many similarities, the inflammatory myopathies differ in their clinical, pathological and treatment realms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000241DOI Listing
December 2018
3 Reads

Cardiovascular Effects of Drugs Used to Treat Attention Deficit/Hyperactivity Disorder Part 2: Impact on Cardiovascular Events and Recommendations for Evaluation and Monitoring.

Cardiol Rev 2018 Dec 7. Epub 2018 Dec 7.

Division of Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, Missouri.

A variety of psychostimulant and non-psychostimulant medications have proven to be successful in reducing inattention, impulsivity and hyperactivity in individuals with attention-deficit/hyperactivity disorder with (ADHD). Psychostimulants used to treat ADHD include methylphenidate and related drugs and various amphetamine preparations. Non-psychostimulant medications used to treat ADHD include atomoxetine and two alpha-2 adrenergic agonists; guanfacine extended-release and clonidine extended-release. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000234DOI Listing
December 2018
2 Reads

Cardiac Applications of Dual-Energy Computed Tomography.

Cardiol Rev 2018 Dec 7. Epub 2018 Dec 7.

New York Medical College/Westchester Medical Center, Valhalla, NY.

Computed tomography is an established tool in the assessment of cardiac anatomy and function. As demonstrated by single photon emission computed tomography, positron emission tomography, and magnetic resonance, the noninvasive evaluation of coronary hemodynamics is an important step in guiding clinical management. Nevertheless, no single modality has been shown to accurately quantify coronary artery stenosis, evaluate an atherosclerotic plaque's composition for embolic risk stratification and assess myocardial perfusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000242DOI Listing
December 2018
1 Read

Racial Disparities in the Cardiac Computed Tomography Assessment of Coronary Artery Disease: Does Gender Matter.

Cardiol Rev 2019 Jan/Feb;27(1):14-22

Department of Surgery, Westchester Medical Center, Valhalla, NY.

Coronary heart disease (CHD) represents a significant healthcare burden in terms of hospital resources, morbidity, and mortality. Primary prevention and early detection of risk factors for the development of CHD are pivotal to successful intervention programs and prognostication. Yet, there remains a paucity of evidence regarding differences in the assessment of these risk factors and the tools of assessment among different ethnicities. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00045415-201901000-0000
Publisher Site
http://dx.doi.org/10.1097/CRD.0000000000000206DOI Listing
December 2018
13 Reads

Gastrointestinal Bleeding During Continuous-Flow Left Ventricular Assist Device Support: State of the Field.

Cardiol Rev 2019 Jan/Feb;27(1):8-13

Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467.

Continuous-flow left ventricular assist devices (CF-LVADs) are increasingly used for the management of advanced heart failure refractory to optimal medical therapy. Despite the encouraging outcomes with CF-LVADs, gastrointestinal bleeding (GIB) continues to be a rather concerning complication resulting in increased rates of readmission and increased morbidity. The exact pathophysiology of CF-LVAD-associated GIB remains poorly understood, and this lack of knowledge limits our ability to control this morbid complication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000212DOI Listing
December 2018
4 Reads
2.407 Impact Factor

Left Atrial Appendage Occlusion in the Management of Stroke in Patients With Atrial Fibrillation.

Cardiol Rev 2018 Dec 4. Epub 2018 Dec 4.

Division of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, NY.

Atrial fibrillation (AF) is associated with a substantially higher risk of thromboembolism, particularly stroke events, resulting in significant morbidity and mortality. Oral anticoagulation (OAC), while effective in reducing embolic events in AF patients, is associated with an increased bleeding risk. Thus, not all patients with AF are candidates for OAC and some are only candidates for OAC in the short term. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000240DOI Listing
December 2018
11 Reads
2.407 Impact Factor

Vulnerable Plaque: A Review of Current Concepts in Pathophysiology and Imaging.

Cardiol Rev 2018 Nov 26. Epub 2018 Nov 26.

From the Department of Medicine, Cardiology Division, New York Medical College/ Westchester Medical Center, Valhalla, NY, USA.

Advances in our understanding of the natural history and biology of atherosclerotic vascular disease led to the concept of a vulnerable plaque (VP), which is predisposed towards more rapid progression and acute coronary events. With newer technologies, we now have at our disposal high quality imaging studies, both invasive and noninvasive, which show promise in identifying plaque characteristics that make it more vulnerable. Upcoming trials aim to evaluate the utility of imaging VP in predicting clinical events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000238DOI Listing
November 2018
2 Reads

Cardiotoxicity of Cancer Therapies.

Cardiol Rev 2018 Nov 14. Epub 2018 Nov 14.

From the Cardiology Division, and the Department of Medicine, Westchester Medical Center/ and New York Medical College, Valhalla, NY, USA.

Cardiotoxicity is a known complication of many cancer therapies. While the cardiotoxicity of established agents such as anthracyclines, antimetabolites and alkylating agents is well known, it is important to realize that newer anticancer therapies such as tyrosine kinase inhibitors, angiogenesis inhibitors, and checkpoint inhibitors are also associated with significant adverse cardiovascular effects. Echocardiography, magnetic resonance imaging, and radionuclide imaging have been used to identify these complications early and prevent further consequences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000239DOI Listing
November 2018
14 Reads

Pre-Cardiogenic Shock: A New Clinical Entity.

Cardiol Rev 2018 Nov 2. Epub 2018 Nov 2.

Department of Cardiovascular Medicine; Tulane University Heart and Vascular Institute, New Orleans, Louisiana, US.

The pathogenesis of cardiogenic shock has evolved from an acute event due to a large myocardial infarction to a semi-acute event due to rapid hemodynamic deterioration on a background of preexisting left ventricular systolic dysfunction. Pre-cardiogenic shock refers to the period of rapid hemodynamic deterioration that precedes overt cardiogenic shock with hypotension, inflammatory response and end-organ failure. Mortality remains extremely high in cardiogenic shock and has not improved over the past decades. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000237DOI Listing
November 2018
3 Reads

Effects of Spaceflight on Cardiovascular Physiology and Health.

Cardiol Rev 2018 Oct 25. Epub 2018 Oct 25.

the Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

During spaceflight, the human cardiovascular system undergoes major changes primarily related to the effects of decreased gravitational force, or microgravity, on the human body. These changes present challenges to human adaptation and operation in space. This article reviews the knowledge gained in human experiments in the past half century of spaceflight, and summarizes our knowledge on the effects of short- and long-duration microgravity exposure on cardiovascular physiology and functioning, including fluid redistribution, autonomic reflexes, cardiac parameters, orthostatic intolerance, arrhythmias, aerobic capacity, and cardiac atrophy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000236DOI Listing
October 2018
2 Reads

The Predicament of Gastrointestinal Bleeding in Patients with a Continuous Flow Left Ventricular Assist Device: Pathophysiology, Evaluation and Management.

Cardiol Rev 2018 Oct 25. Epub 2018 Oct 25.

Department of Surgery, Division of Cardiothoracic Surgery, New York Medical College/Westchester Medical Center, Valhalla, NY.

Heart failure affects over 5 million Americans, with numbers expected to rise. While heart transplantation is the most effective long-term strategy for end-stage heart failure, there is a limited cardiac donor pool, and these organs are often unavailable at the time of need. Left ventricular assist devices (LVADs), therefore, continue to be used to bridge this gap. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00045415-900000000-9972
Publisher Site
http://dx.doi.org/10.1097/CRD.0000000000000235DOI Listing
October 2018
19 Reads

Cardiovascular Effects of Drugs Used to Treat Attention Deficit/Hyperactivity Disorder Part 1: Epidemiology, Pharmacology, and Impact on Hemodynamics and Ventricular Repolarization.

Cardiol Rev 2018 Oct 25. Epub 2018 Oct 25.

Division of Cardiovascular Medicine, University of Missouri School of Medicine , Columbia, Missouri.

Attention-deficit/hyperactivity disorder (ADHD) is a clinical syndrome characterized by persistent inattention, impulsivity and hyperactivity. It is most commonly encountered in children and adolescents, but may persist into adulthood. A variety of psychostimulant and non-psychostimulant medications have proven to be successful in reducing inattention, impulsivity and hyperactivity in those with ADHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000233DOI Listing
October 2018
19 Reads

Michael E. DeBakey, Surgeon, Scientist, Innovator, and Administrator (1908-2008).

Authors:
George L Hines

Cardiol Rev 2019 Mar/Apr;27(2):57-59

Division of Vascular Surgery, NYU Winthrop Hospital, Mineola, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000232DOI Listing
October 2018
2 Reads

Andexanet Alfa for Reversing Factor Xa Inhibition.

Cardiol Rev 2019 Mar/Apr;27(2):108-111

From the Department of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of New Mexico, Albuquerque, New Mexico.

The direct oral anticoagulants (DOACs) have gained popularity recently among both patients and providers for their comparable or better efficacy and safety profiles compared with warfarin and the lack of need for routine monitoring of anticoagulant effect. One obstacle for the more widespread use of the DOACs in clinical practice has been the lack of a reversal agent. Most DOACs act by directly binding to and inhibiting the effects of factor Xa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000230DOI Listing
October 2018
11 Reads

Overview of Link Between Inflammatory Bowel Disease and Cardiovascular Disease.

Cardiol Rev 2018 Nov/Dec;26(6):287-293

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

Inflammation has been shown to play an increasingly important role in the pathogenesis of atherosclerosis and in precipitating thrombotic events. Inflammatory bowel disease (IBD) is a systemic inflammatory disorder with a wide range of extraintestinal manifestations including a clinically significant increase in the risk of venous thromboembolism compared to matched controls in several studies. The data for the association between IBD and ischemic heart disease are less clear; multiple population-based studies have shown both positive and negative associations between the 2 conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000214DOI Listing
November 2018
13 Reads

Ten Trials of a Cardiovascular Clinical Trialist.

Cardiol Rev 2019 Jan/Feb;27(1):1-7

Division of Cardiology, Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000229DOI Listing
September 2018
2 Reads

Evolving Use of Biomarkers in the Management of Heart Failure.

Cardiol Rev 2018 Sep 5. Epub 2018 Sep 5.

Duke Same-Day Access Clinic Advanced Heart Failure Health, Durham, NC.

Objective, noninvasive, clinical assessment of patients with heart failure can be made using biomarker measurements, including natriuretic peptides, cardiac troponins, soluble suppression of tumorigenicity-2, and galectin-3. The aim of this review is to provide clinicians with guidance on the use of heart failure biomarkers in clinical practice. The authors provide a didactic narrative based on current literature, an exemplary case study, and their clinical experience. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000224DOI Listing
September 2018
1 Read

Long-Term Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in End-Stage Renal Disease Patients on Dialysis: A Systematic Review and Meta-Analysis.

Cardiol Rev 2018 Nov/Dec;26(6):277-286

Division of Cardiology, New York Medical College and Westchester Medical Center, Valhalla, NY.

There are no dedicated data to guide drug-eluting stent (DES) versus bare-metal stent (BMS) selection in patients with end-stage renal disease undergoing dialysis (ESRD-D). It is unclear whether long-term benefits of a specific stent type outweigh risks in this population at high risk for both bleeding and ischemic events. We performed a meta-analysis of nonrandomized studies extracted from PubMed, Scopus, and EMBASE, assessing the safety and effectiveness of DES versus BMS in ESRD-D patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000192DOI Listing
November 2018
9 Reads
2.410 Impact Factor

Hearts and Minds: Stress, Anxiety, and Depression. Unsung Risk Factors for Cardiovascular Disease.

Cardiol Rev 2018 Aug 20. Epub 2018 Aug 20.

Heart and Vascular Institute, Hartford Hospital, Hartford, Ct.

Anxiety, depression and stress are exceedingly common in patients with cardiovascular disease (CVD). They increase the risk of cardiac events and are associated with much worse outcomes. A causal relationships exists between anxiety/depression and adverse cardiac events such as acute myocardial infarction and sudden cardiac death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000228DOI Listing
August 2018
1 Read

Interatrial Shunting, a Novel Device-Based Therapy for Patients With Heart Failure.

Cardiol Rev 2018 Sep/Oct;26(5):267-273

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

Heart failure (HF) patients with either reduced ejection fraction or preserved ejection fraction experience a high mortality rate. The most recent pharmacologic advance for treating patients with HF with reduced ejection fraction has been with sacubitril/valsartan. Along with pharmaceutical research, there has been interest in device-based therapies as another treatment approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000199DOI Listing
November 2018
1 Read

Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.

Cardiol Rev 2018 Nov/Dec;26(6):331-338

Department of Clinical Health Professions, College of Pharmacy and Health Sciences, St John's University, Queens, NY, and Divisions of Geriatric Medicine & Pharmacy, NYU Winthrop University Hospital, Mineola, NY.

Venous thromboembolism (VTE) is a common and preventable cause of morbidity and mortality in hospitalized patients. Low-molecular-weight heparin, low-dose unfractionated heparin, fondaparinux, and warfarin have been the mainstay options for the prevention and treatment of VTE before the emergence of nonvitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban. Despite the advantages of NOACs in improving patient adherence, none of them are approved for the prevention of VTE in acutely ill medical patients at high risk of thromboembolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000227DOI Listing
November 2018
7 Reads

Cardiovascular Effects of Chemotherapy Used in the Treatment of Breast Cancers.

Cardiol Rev 2019 Mar/Apr;27(2):87-96

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

Attempts to carry out clinical trials to improve the treatment of breast cancers, including chemotherapy and targeted oncologic therapies, often exclude women with baseline cardiovascular compromise, such as low ejection fraction or arrhythmia. Therefore, despite concrete evidence of cardiotoxicity from a select number of chemotherapeutic agents, it has been difficult to better characterize the progression of cardiac dysfunction in women with preexisting cardiac conditions who receive chemotherapy. Women who have impaired cardiac function should be included in future clinical trials, or at least placed in separate trials with careful monitoring, to better assess this high-risk population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000225DOI Listing
July 2018
21 Reads

Impact of Implantable Cardioverter-Defibrillator Interventions on All-Cause Mortality in Heart Failure Patients - A Meta-Analysis.

Cardiol Rev 2018 Jul 26. Epub 2018 Jul 26.

Second Department of Cardiology, University of Ioannina, School of Medicine, Ioannina, Greece.

Implantable cardioverter-defibrillators (ICDs) have a unique role in the primary and secondary prevention of sudden cardiac death. However, appropriate and inappropriate ICD interventions [anti-tachycardia pacing (ATP) or shocks] can result in deleterious effects. The aim of our study was to systematically review the existing data about the impact of ICD interventions on all-cause mortality in heart failure patients with reduced ejection fraction (HFrEF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000226DOI Listing
July 2018
2 Reads

Cardiac Involvement in Systemic Sclerosis: Diagnostic Tools and Evaluation Methods.

Cardiol Rev 2019 Mar/Apr;27(2):73-79

From the Department of Internal Medicine, Connective Tissue Diseases and Geriatrics.

The heart is one of the major organs commonly involved in systemic sclerosis (SSc). Myocardial fibrosis has been identified in a high percentage of these patients. Most SSc patients with cardiac involvement (CI) are subclinical, especially early on in the course of their disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000221DOI Listing
July 2018
13 Reads

Functional Mitral Regurgitation: An Interventional Cardiologist's Perspective.

Cardiol Rev 2018 Sep/Oct;26(5):230-238

From the Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.

Functional mitral regurgitation (FMR) is common in patients with heart failure and portends a poor prognosis. The etiology is secondary to nonischemic or ischemic (postmyocardial infarction) adverse remodeling. Treatment includes guideline-directed medical therapy, cardiac resynchronization therapy, and in some cases, surgical repair or replacement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000219DOI Listing
November 2018
3 Reads

Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases.

Cardiol Rev 2019 Jan/Feb;27(1):49-56

From the Department of Medicine.

Bempedoic acid (BA; ETC-1002) is a new agent that reduces cholesterol synthesis through inhibition of adenosine triphosphate citrate lyase, an enzyme upstream from 3-hydroxy-3-methylglutaryl-coenzyme A. In animal models, BA also influences fatty acid synthesis, but in humans, its role is limited primarily to lowering low-density lipoprotein cholesterol (LDL-C). In early clinical trials, BA was well tolerated and without major side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000218DOI Listing
June 2018
3 Reads
2.410 Impact Factor

Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy.

Cardiol Rev 2019 Mar/Apr;27(2):97-107

Department of Medicine, Division of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, NY.

Immune checkpoint inhibitors present clinicians with both an exciting step forward in cancer treatment and the unknown possibilities of an unshackled immune system. The latter phenomena, known as immune-related adverse events (irAEs), are of particular interest because they may affect any organ system with autoimmune-like pathologies, such as hepatitis and colitis. Within the cardiovascular system, irAEs associated with immune checkpoint blockade exist as a broad clinical spectrum, with autoimmune myocarditis being the best-characterized entity at this time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000217DOI Listing
June 2018
4 Reads

Obesity in Kidney Transplantation: Impact on Transplant Candidates, Recipients, and Donors.

Cardiol Rev 2019 Mar/Apr;27(2):63-72

From the Division of Nephrology/Kidney Transplant Service, Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

Obesity is now common among children and adults who are kidney transplant candidates and recipients. It is associated with an increased risk of cardiovascular disease and kidney failure. This also pertains to potential living kidney donors with obesity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000216DOI Listing
June 2018
2 Reads

A Nonsurgical Approach to Mesenteric Vascular Disease: Erratum.

Authors:

Cardiol Rev 2018 Jul/Aug;26(4):218

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000208DOI Listing
June 2018
3 Reads

Acromegalic Cardiomyopathy: An Overview of Risk Factors, Clinical Manifestations, and Therapeutic Options.

Cardiol Rev 2018 Nov/Dec;26(6):307-311

Division of Cardiology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY.

Acromegaly is a rare endocrine disorder that carries a significant burden of cardiovascular morbidity and mortality. Abnormalities of the growth hormone/insulin-like growth factor-1 axis in acromegaly lead to the characteristic cardiovascular manifestations of this disease. One hallmark feature of the disease is acromegalic cardiomyopathy, a syndrome of progressive cardiac dysfunction characterized by left ventricular hypertrophy, diastolic dysfunction, and combined systolic and diastolic dysfunction in the very advanced stage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000215DOI Listing
November 2018
3 Reads

Left Main Disease: What Is the Correct Approach to Revascularization?

Cardiol Rev 2018 Sep/Oct;26(5):219-229

From the Division of Cardiology, Emory University School of Medicine, Atlanta, GA.

Percutaneous coronary intervention of the left main coronary artery has evolved through registries and meta analyses, supported by results from the EXCEL [Everolimus-Eluting Stents (EES) or Bypass Surgery for Left Main Coronary Artery Disease] and NOBLE (Percutaneous Coronary Angioplasty versus Coronary Artery Bypass Grafting in Treatment of Unprotected Left Main Stenosis) trials as an acceptable alternative to coronary artery bypass grafting in patients with low and intermediate Syntax scores. Advances in stenting strategies and the availability of larger diameter drug-eluting stents improve patient safety and optimize procedural and patient outcomes. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00045415-900000000-9973
Publisher Site
http://dx.doi.org/10.1097/CRD.0000000000000213DOI Listing
November 2018
5 Reads

GI Bleeding During CF-LVAD Support: State of the Field.

Cardiol Rev 2018 May 9. Epub 2018 May 9.

Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467, USA.

Continuous-flow left ventricular assist devices (CF-LVADs) are increasingly used for the management of advanced heart failure refractory to optimal medical therapy. Despite the encouraging outcomes with CF-LVADs, gastrointestinal bleeding (GIB) continues to be a rather concerning complication resulting in increased rates of readmission and increased morbidity. The exact pathophysiology of CF-LVAD associated GIB remains poorly understood and this lack of knowledge limits our ability to control this morbid complication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000212DOI Listing
May 2018
2 Reads
2.410 Impact Factor

Novel Pharmacotherapy in Hypertrophic Cardiomyopathy.

Cardiol Rev 2018 Sep/Oct;26(5):239-244

Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla, NY.

Hypertrophic cardiomyopathy (HCM) is an inherited disease characterized by unexplained left ventricular hypertrophy. Although it is estimated to affect 1 out of 500 people, the HCM gene carrier prevalence is much more common, probably as high as 1 in 200 people. Most affected individuals have a normal life expectancy, whereas some patients may develop sudden cardiac death or end-stage heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000211DOI Listing
November 2018
5 Reads
2.410 Impact Factor

Are Shorter Durations of Dual Antiplatelet Therapy Acceptable Following Percutaneous Coronary Intervention?

Cardiol Rev 2018 Jul/Aug;26(4):213-217

The University of New Mexico College of Pharmacy, Albuquerque, NM.

Much debate has centered on whether or not the standard 12-month duration of dual antiplatelet therapy (DAPT) is still necessary postpercutaneous coronary intervention, given recent improvements in stent technology. The benefits of shorter (3-6 months) durations of DAPT include a potential lower risk for bleeding and less patient drug cost and pill burden. Although randomized clinical trials have shown noninferiority for shorter versus longer DAPT regimens in many regards, some endpoints (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000209DOI Listing
October 2018
5 Reads

Exercise for Preventing Hospitalization and Readmission in Adults With Congestive Heart Failure.

Cardiol Rev 2019 Jan/Feb;27(1):41-48

Elsevier Evidence-Based Medicine Center, Philadelphia, PA.

We critically appraised all available evidence regarding exercise interventions for improving patient survival and reducing hospital admissions in adults with chronic heart failure (HF). We searched 4 databases up to April 2018 and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation working group approach. We reviewed 7 meta-analyses and the publications of 48 randomized controlled trials (RCTs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000210DOI Listing
May 2018
5 Reads

Review on Factors Influencing Physician Guideline Adherence in Cardiology.

Cardiol Rev 2019 Mar/Apr;27(2):80-86

From the Department of Cardiology, Catharina Hospital Eindhoven.

Cardiovascular disease is the most common cause of death in Western countries. Physician adherence to guidelines is often suboptimal, resulting in impaired patient outcome and prognosis. Multiple studies have been conducted to evaluate patterns and the influencing factors of patient adherence, but little is known about factors influencing physician guideline adherence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000207DOI Listing
April 2018
4 Reads

Sudden Cardiac Death in Hypertrophic Cardiomyopathy.

Cardiol Rev 2018 May/Jun;26(3):145-151

From the Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland.

Hypertrophic cardiomyopathy (HCM) is a heart disease characterized by hypertrophy of the left ventricular myocardium and is most often caused by mutations in sarcomere genes. The structural and functional abnormalities are not explained by flow-limiting coronary artery disease or loading conditions. The disease affects at least 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000184DOI Listing
September 2018
9 Reads

Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures.

Cardiol Rev 2018 Sep/Oct;26(5):245-254

Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, TN.

As direct oral anticoagulants (DOACs) have demonstrated favorable efficacy and safety outcomes compared with vitamin K antagonists for the treatment and prevention of venous thromboembolism and the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, their role in the management of anticoagulation during electrophysiological procedures continues to evolve. At present, guidelines are limited regarding specific recommendations for the use of DOACs in these clinical settings. Here, we review available data regarding the risks and benefits associated with various periprocedural anticoagulation management approaches when patients receiving DOACs undergo electrophysiologic procedures including cardioversion, ablation, and device implantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082596PMC
November 2018
13 Reads

The Physiological Rationale for Incorporating Pulsatility in Continuous-Flow Left Ventricular Assist Devices.

Cardiol Rev 2018 Nov/Dec;26(6):294-301

From the Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Institute, University Health Network, University of Toronto, Toronto, Canada.

Over the past few decades, left ventricular assist device (LVAD) support has extended the lives of many patients with end-stage heart failure. The most common devices are continuous-flow (CF) LVADs. The use of the CF-LVADs has required that clinicians learn the physiological and clinical consequences of long-term continuous blood flow. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000202DOI Listing
November 2018
4 Reads

Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit.

Authors:
Rinkoo Dalan

Cardiol Rev 2018 Nov/Dec;26(6):312-320

From the Department of Endocrinology, Division of Medicine, Tan Tock Seng Hospital, Singapore; Department of Metabolic Medicine, Lee, Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Department of General Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). However, conventional antihyperglycemic medications seem to have minimal effect on lowering CV risk despite achieving excellent reductions in glycated hemoglobin A1c and associated reductions in microvascular risk. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as noteworthy antihyperglycemic agents with concomitant CV and renal protection in T2DM patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000201DOI Listing
November 2018
61 Reads
2.410 Impact Factor

INTER-ATRIAL SHUNTING, A NOVEL DEVICE-BASED THERAPY FOR PATIENTS WITH HEART FAILURE.

Cardiol Rev 2018 Mar 30. Epub 2018 Mar 30.

Departments of Medicine, New York Presbyterian/Weill-Cornell Medical Center, New York, NY and New York Medical College/Westchester Medical Center, Valhalla, NY.

Heart failure patients with either reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) experience a high mortality rate. The most recent pharmacologic advance for treating patients with HFrEF has been with sacubitril/valsartan. Along with pharmaceutical research, there has been interest in device-based therapies as another treatment approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000199DOI Listing
March 2018
3 Reads

Risk-Adjusted Overall Mortality as a Quality Measure in the Cardiovascular Intensive Care Unit.

Authors:
Michael Goldfarb

Cardiol Rev 2018 Nov/Dec;26(6):302-306

From the Division of Cardiology, Jewish General Hospital, McGill University, Montreal, QC, Canada.

Risk-adjusted mortality has been proposed as a quality of care indicator to gauge cardiovascular intensive care Unit (CICU) performance. Mortality is easily measured, readily understandable, and a meaningful outcome for the patient, provider, administrative agencies, and other key stakeholders. Disease-specific risk-adjusted mortality is commonly used in cardiovascular medicine as an indicator of care quality, for external accreditation, and to determine payer reimbursement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000200DOI Listing
November 2018
3 Reads

Xenon: An Emerging Neuroprotectant With Potential Application for Cardiac Arrest Care.

Cardiol Rev 2018 Jul/Aug;26(4):207-212

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York.

Xenon is an inert, highly polarizable noble gas with demonstrated safety and application in general anesthesia for over 50 years. A potent inhibitor of the N-methyl-D-aspartate subtype of glutamate receptors, xenon has a well-documented ameliorating effect on excitotoxic neuronal injury in numerous cellular and animal models of hypoxic-ischemic brain injury. The most important determinant of overall survival and morbidity in out-of-hospital cardiac arrest is the severity of neurological injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000198DOI Listing
October 2018
4 Reads

Through the Decades: β-Blocker Use and Outcomes in Acute Coronary Syndromes.

Cardiol Rev 2018 May/Jun;26(3):157-166

From the Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD.

Beta-adrenergic receptor antagonists, or β-blockers, have been a cornerstone of treatment in patients with acute coronary syndromes (ACS) for more than 4 decades. First studied in the 1960s, β-blockers in ACS have been shown to decrease the risk of death, recurrent ischemic events, and arrhythmias by reducing catecholamine-mediated effects and reducing myocardial oxygen demand. Through the decades, the β-blocker of choice, timing of initiation, duration of therapy, and dosing have evolved considerably. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000197DOI Listing
September 2018
8 Reads

Frank Cole Spencer, MD-Surgeon, Innovator, and Educator.

Authors:
George Hines

Cardiol Rev 2018 Jul/Aug;26(4):167-168

Department of Cardiovascular and Thoracic Surgery, New York University-Winthrop University Hospital, Mineola, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000196DOI Listing
October 2018
3 Reads

Diagnosis, Treatment, and Management of Orthotopic Liver Transplant Candidates With Portopulmonary Hypertension.

Cardiol Rev 2018 Jul/Aug;26(4):169-176

Division of Transplant Hepatology, New York Medical College/Westchester Medical Center, Valhalla, NY.

Portopulmonary hypertension (POPH) is seen in 5-8% of orthotopic liver transplantation (OLT) candidates and has significant implications for clinical outcomes. POPH is characterized by vasoconstriction and remodeling of the pulmonary vasculature. It is exacerbated by the hyperdynamic circulation that is common in advanced liver disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000195DOI Listing
October 2018
20 Reads
2.410 Impact Factor